A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

Having met the primary endpoint in the pivotal CARDINAL trial, Sanofi’s sutimlimab could become the first approved therapy for primary cold agglutinin disease.

According to the company, the data are the first Phase III results for a complement inhibitor in the indication, which is a rare autoimmune

Read the full 460 word article

User Sign In